

Company Announcement



Tuesday 28 November, 2014

By e-lodgement

Manager Companies  
Company Announcements Office  
Australian Securities Exchange Limited  
Level 4, Stock Exchange Centre  
20 Bridge Street  
SYDNEY NSW 2000

Dear Sir/Madam,

**Results of Annual General Meeting**

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Yours faithfully,

A handwritten signature in black ink, appearing to be "Darren Keamy", written over a faint watermark.

Darren Keamy  
Company Secretary

For personal use

## Annual General Meeting

## 1) Adoption of Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
11,874,174	1,038,735	42,449	217,333

The motion was carried as an ordinary resolution on a show of hands.

## 2) Re-election of Mr Elie Ishag

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
12,793,262	907,354	82,915	317,333

The motion was carried as an ordinary resolution on a show of hands.

## 3) Approval to vary the issue price of the Shares

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
11,939,476	1,015,581	78,148	344,546

The motion was carried as an ordinary resolution on a show of hands.

## 4) Ratification and approval of previous allotment

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
5,955,434	891,555	43,321	315,333

The motion was carried as an ordinary resolution on a show of hands.

## 5) Approval issue of Shares to Dr Philippe Wolgen

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
12,292,351	896,492	63,583	315,333

The motion was carried as an ordinary resolution on a show of hands.

## 6) Approval issue Shares to San Luis Nominees Pty Ltd

The instructions given to validly appointed proxies in respect of the resolution were as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Proxy's discretion</b>
12,618,839	899,503	115,984	346,530

The motion was carried as an ordinary resolution on a show of hands.

**7) Approval issue Shares Elie Ishag & Rosetta Ishag**

The instructions given to validly appointed proxies in respect of the resolution were as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Proxy's discretion</b>
12,744,472	985,361	118,250	252,781

The motion was carried as an ordinary resolution on a show of hands.

**8) Approval of Performance Rights Plan**

The instructions given to validly appointed proxies in respect of the resolution were as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Proxy's discretion</b>
11,426,921	1,257,806	267,617	320,347

The motion was carried as an ordinary resolution on a show of hands.

**9) Approve grant performance rights Philippe Wolgen**

The instructions given to validly appointed proxies in respect of the resolution were as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Proxy's discretion</b>
11,068,133	1,627,124	259,894	317,540

The motion was carried as an ordinary resolution on a show of hands.

**10) Approve grant performance rights to Stan McLiesh**

The instructions given to validly appointed proxies in respect of the resolution were as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Proxy's discretion</b>
11,256,351	1,414,900	277,943	323,497

The motion was carried as an ordinary resolution on a show of hands.

**11) Approve grant performance rights Brenda Shanahan**

The instructions given to validly appointed proxies in respect of the resolution were as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Proxy's discretion</b>
11,161,000	1,513,366	280,928	317,397

The motion was carried as an ordinary resolution on a show of hands.

**12) Approve grant performance rights to Elie Ishag**

The instructions given to validly appointed proxies in respect of the resolution were as follows:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Proxy's discretion</b>
11,176,000	1,499,505	280,928	316,258

For personal use only

The motion was carried as an ordinary resolution on a show of hands.

### 13) Approval of 10% Placement Facility

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
12,371,173	1,156,357	292,076	316,258

The motion was carried as a special resolution on a show of hands.

- End -

### About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. Clinuvel's lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been recommended for marketing authorisation under exceptional circumstance by the European Medicines Agency. Based in Melbourne, Australia, Clinuvel has operations in Europe, the US and Singapore.

For more information go to <http://www.clinuvel.com>.

Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, SCENESSE® (afamelanotide) for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

Level 14 / 190 Queen Street  
Melbourne, Victoria 3000  
Australia

T +61 3 9660 4900  
F +61 3 9660 4999

[www.clinuvel.com](http://www.clinuvel.com)